NY-INNOVATIVE-HEALTH
Andrew Sealfon, Chairman and Founder of Innovative Health Sciences LLC (“IHS”), today pledged 1,000 of his company’s unique portable non-electric IV pumps to victims of the Ukraine conflict.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005921/en/
The Insignis™ Syringe Infusion System includes a fully mechanical, non-electric infusion pump system and dedicated flow control devices for both intravenous and subcutaneous applications. The portable system operates independent of battery or electricity, allowing it to be stockpiled, transported, and stored for emergency situations in locations where resources may be scarce or absent. The Insignis™ system has undergone extensive testing and received ISO 13485 quality management system and CE mark certification in May 2021. The CE (Conformité Européene) mark enables IHS to sell the system throughout the European Union.
Unlike other infusers, the Insignis™ system enables the rate to be titrated and adjusted easily and quickly without drip chambers or inaccurate rate controllers. It consists of:
- Mechanical 13.5psi Syringe Driver
- Intravenous Controller
- OneSett™ Subcutaneous Administration Set
This system addresses 80-90% of the needs of infusion therapy, providing simplicity, safety, versatility, and usability. In emergency situations, it may be used for:
- Hypodermoclysis (subcutaneous rehydration when intravenous access is not feasible)
- Antibiotics or antivirals
- Fluid volume assist medications
The atrocities currently taking place in Ukraine have destroyed hospitals, wards, and care centers, crippling medical efforts. Sealfon and IHS are pledging 1,000 infusion pumps to help patients receive the care they most desperately need, as well as any education needed for optimal use of the system for Ukrainian soldiers and civilians.
The 1,000 Insignis™ pumps will be available for delivery over the next 60 days, and will be provided to third party agencies and bodies serving the victims of the conflict.
Sealfon and IHS are also coordinating private donations and setting up a GoFundMe page to allow for others to contribute additional Insignis™ pumps and ancillary supplies to victims of the Ukraine conflict. For more information, contact info@innohealthsci.com or visit https://gofund.me/508a32c3 .
About Innovative Health Sciences
New York-based Innovative Health Sciences, LLC provides innovative solutions to the infusion healthcare market. IHS’ approach is patient-centric and future-oriented; our goal is to provide the highest quality of life by empowering the patient to take control of their infusion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005921/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer19.1.2026 08:30:00 CET | Press release
Based on DESTINY-Breast09 phase 3 trial results that showed Daiichi Sankyo and AstraZeneca’s ENHERTU in combination with pertuzumab significantly improved progression-free survival versus current first-line standard of care in HER2 positive metastatic breast cancer The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY
Syngenta to Address Global Agricultural Challenges at WEF, Championing AI to Empower Farmers and Create Open Technology Access19.1.2026 08:00:00 CET | Press release
AI and digital tools are unlocking unprecedented opportunities to strengthen farms and secure food security. New IPSOS study reveals technology adoption gap, underscoring urgent need for equitable technology access. Syngenta champions "Agricultural Intelligence" at World Economic Forum, showcasing Cropwise AI solutions that put cutting-edge tools in the hands of all farmers, especially smallholders. As farmers globally grapple with unprecedented economic, geopolitical, and environmental pressures; the agricultural sector faces a continued contraction. An alarming decrease in active farms worldwide and rising financial distress underscore the urgent need for innovation and technology to ensure a resilient food system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118646017/en/ Jeff Rowe, Syngenta Group CEO "Farmers today are navigating one of the most complex periods in modern agriculture, facing pressures that demand urg
KPMG Enters Strategic Relationship With Uniphore to Build AI Agents Powered by Industry-Specific Small Language Models19.1.2026 07:00:00 CET | Press release
Collaboration uses KPMG’s knowledge in small language models to accelerate delivery of business outcomes to clients across banking, insurance, energy and healthcare Uniphore, the Business AI company, today announced a strategic relationship with KPMG LLP to operationalize AI agents across internal and client-facing workflows, supporting the firm’s continued effort to move from experimental AI pilots to production-grade deployment. As part of the collaboration, KPMG will work with Uniphore to build AI agents using Uniphore’s Business AI Cloud as a platform for agentic AI and fine-tuned small language models (SLMs), supporting clients across regulated industries including banking, insurance, energy and healthcare. Built on a sovereign, composable, and secure architecture, the platform integrates with KPMG’s existing enterprise systems and data environments, meeting governance and compliance requirements essential to regulated industries. This initiative reflects KPMG’s broader effort to
International Chamber of Commerce, Carbon Measures Announce First Group of Global Experts for Carbon Accounting Panel19.1.2026 06:00:00 CET | Press release
Panelists include senior global leaders from business, academia, and civil society. The International Chamber of Commerce (ICC) and Carbon Measures today announced the first cohort of experts selected to serve on the Technical Expert Panel on Carbon Accounting, which will define the principles, scope and real-world applications of a carbon emissions accounting system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118104674/en/ The panelists are distinguished leaders and experts across industry, science, civil society, and academia – representing diverse disciplines, geographies, and professional backgrounds. The panel will apply their experience across sustainability, technology, public policy, and industrial and financial systems to establish a timely, accurate and verifiable ledger-based carbon emissions accounting system. This system will track product-level emissions across the value chain and support real-world deci
AI-Powered Creator Monetisation Platform, Fanvue, Hits $100m Run Rate and Raises $22m Series A Investment - as Leading Global Creators Rush to Join the Platform19.1.2026 01:01:00 CET | Press release
Fanvue, the AI-powered creator monetisation platform with a $100m-plus run rate, has announced a $22m Series A investment round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112458975/en/ Joel Morris, Will Monange and Harry Fitzgerald (left to right) Fanvue has bet big on AI-powered tools changing the face of an industry estimated to be worth over $500B by 2030. The platform, which recently crossed $100m annualised revenue, has over 17 million monthly active users, and is home to 250,000 creators who are using Fanvue’s pioneering AI tools to scale their businesses and earn. Instead of competing with legacy platforms, Fanvue is defining a new category, the Creator AI Economy. Fanvue’s belief is that the next generation of creators will accelerate their earnings through utilising technology. And it’s happening in real time. According to Fanvue, just over 93% of creators on the platform used at least one of the platform’s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom